Game-changing COVID-19 tests are needed to fight the pandemic and Abbott has just developed one — a rapid antigen test called the BinaxNOW^TM COVID-19 Ag Card — which received Emergency Use Authorization from the U.S. Food and Drug Administration.

In a recent CNBC op-ed, Abbott President and Chief Executive Officer Robert Ford examines how BinaxNOW and its complementary mobile app, called NAVICA^TM, could help make testing more accessible and give people some peace of mind amidst the uncertainty.

Read the op-ed.

The BinaxNOW^TM COVID-19 Ag Card EUA has not been FDA cleared or approved. It has been authorized by the FDA under an emergency use authorization for use by authorized laboratories. The test has been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens, and is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.